Downloading...
Download

Corporation

Gravions IG: Why Apple's Shift to India Could Trigger a Drop in Apple is betting heavily on changing its production geography, planning to move a significant portion of iPhone assembly from China to India by 2026. Analysts at Gravions IG have assessed the situation and concluded that this move could negatively impact the company’s stock value in the near term. Key Risks of Production Relocation Indian manufacturing facilities, although growing rapidly, have not yet achieved the level of quality and logistical efficiency seen at Chinese plants. Gravions IG emphasizes that reconfiguring production processes takes time, and potential disruptions in supply chains or reduced quality in the early batches could trigger dissatisfaction among consumers and partners. According to their analysis, the transition could increase product costs and squeeze profit margins, putting pressure on Apple’s financial results over the next few quarters. Investor Reactions Current market behavior reflects investor caution: Apple's share price has already fallen nearly 17% since the start of the year, with technical indicators suggesting further declines. The formation of a "death cross" — where the 50-day moving average crosses below the 200-day moving average — heightens concerns about a prolonged downtrend. Gravions IG stresses that until the Indian production lines are fully operational and stable, Apple's stock will likely remain under selling pressure. Strategic Perspective: Opportunity or Risk? In the long run, diversifying manufacturing could benefit Apple by reducing its dependence on China and insulating it from potential geopolitical or economic shocks. Additionally, the Indian government's efforts to bolster its manufacturing sector could provide Apple with a stronger foundation for future expansion. Still, Gravions IG insists that until Indian facilities reach consistent quality and scale, Apple will be vulnerable to market sentiment swings and potential reputational risks. Conclusion Relocating production is a strategically sound but high-risk move for Apple in the short term. Gravions IG advises investors to closely monitor product quality and supply chain stability in India before making long-term investment decisions regarding Apple's stock.
PYTH:AAPLEducation
by HCN-News12
CGC Potential for Bullish Continuation | 31st January 2023Looking at the H4 chart, my overall bias for CGC is bullish due to the current price crossing above the Ichimoku cloud , indicating a bullish market. Looking for a pullback buy entry at 2.78, where the 23.6% Fibonacci line and overlap support is. Stop loss will be at 2.52, where the previous overlap support is. Take profit will be at 3.43, where the overlap resistance and 50% Fibonacci line is. Any opinions, news, research, analyses, prices, other information, or links to third-party sites contained on this website are provided on an "as-is" basis, as general market commentary, and do not constitute investment advice. The market commentary has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is therefore not subject to any prohibition on dealing ahead of dissemination. Although this commentary is not produced by an independent source, FXCM takes all sufficient steps to eliminate or prevent any conflicts of interest arising out of the production and dissemination of this communication. The employees of FXCM commit to acting in the clients' best interests and represent their views without misleading, deceiving, or otherwise impairing the clients' ability to make informed investment decisions. For more information about the FXCM's internal organizational and administrative arrangements for the prevention of conflicts, please refer to the Firms' Managing Conflicts Policy. Please ensure that you read and understand our Full Disclaimer and Liability provision concerning the foregoing Information, which can be accessed on the website.
NASDAQ:CGCLong
by Rockqet
TARGET PREDICTION!!!!! (SHORT)DESCRIPTION: In the chart above I have provided a macro analysis on what can be the potential path that price action will follow with current ongoing bearish momentum. POINTS: 1. Price Action is in an overall downtrend channel. 2. Within this falling channel we have consolidation occurring with bearish trajectory as seen in the image to the top left in the top right example. 3. We have seen a BREAKOUT to the $139 range recently and if we come to see PULLBACK in the $156 range this would confirm a downward move. *IMPORTANT: PULLBACK POINT COINCIDES WITH TOP OF CHANNEL, SUPPLY FLOOR & 100 & 50 MA. SCENARIO #1: If price action is to lose $125 we will most certainly see a continuation of current bearish momentum which will then place us in the the follow SUPPLY & DEMAND POCKET OF $125 - $75. *NOTE: $125 -$75 SUPPLY & DEMAND POCKET HAS PROVEN TO HAVE WEAK PRICE ACTION IN THE PAST. SCENARIO #2: If price action is to move onto a bullish scenario it is crucial we hold $140 and see enough consolidation in order to invalidate current setup. NYSE:TGT
NYSE:TGTShort
by DGSTBROKERACC
Carnoval Corporation counting its pennies. CCLGoals 0.56, 0.49. Invalidation at 0.89. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:CCLShort
by Rykin_Capital
1
Have corporate bonds bottomed?The Corporate bond market got extremely oversold and it bounced without the Fed having to pivot. Essentially the market got to 2013-2018 levels, and bounced nicely at the old support. But we still don't know whether the bottom is in or now, as there are more questions that need to be answered, like: Does the market expect the Fed to reverse course soon? Does the market think the bottom is in for bond yields? Does it think inflation has peaked? In my opinion the market did the tightening itself without the Fed. The Fed did a mistake for not raising rates and ending QE faster, however they were right on their approach to go slowly, as one way or another inflation would slow down. By inflation slowing down down I don't mean that prices will go down, just that prices will go up a lot less than they did over the last 1-2 years. At the same time I do believe that as inflation comes down, it is possible that we get to see the Fed say that they will pause their hikes after raising them to around 2% and will let their balance sheet roll off on its own. Essentially higher interest rates, lower asset prices, tight fiscal and monetary policy, and already high energy prices are crushing demand. The Fed was/is behind the curve, but as the curve seems to be now moving to the direction of the Fed. To a large extend their objective has been achieved, as this correction was similar to the 2018 correction, only that this time around the correction was welcomed when back then it wasn't. Now I don't really think the bottom is in for corporate bonds, however I also don't think they are going to roll over very quickly. If the food & energy crisis gets worse, I have no doubt that these will get crushed. It just seems that in the short-medium term things will cool down a bit and part of them Fed's goals have been achieved. The US economy remains fairly strong and its corporations are in a fairly good shape, despite everything that has been going in the world over the last few years. Having said all that I don't want to be a buyer of HYG at 80. At those levels I think it is better to short and aim for 77-78, and then if the price action looks decent, go long at those levels. The bounce is too sharp for it to have legs to go higher immediately. I'd expect more chop in the 75-81 area before the market decides whether it is going to go higher or lower.
AMEX:HYG
by BitcoinMacro
4
Realty Income Corp (O): Looking for a Pullback Below 50% FibO has been slowly grinding higher since March 2020 lows topping out at $72.55. Price action since November has been stuck in a range with the January 2022 price action sweeping above the double top highs at $70.40 level. After the sweep higher, price action appears heavy at current pricing especially since the asset has not made any meaningful retracement lower. Currently I am bearish on O with downside objectives being 65.60, 62.50 and 54.50 levels.
NYSE:OShort
by DenisRisticFX
Carnival Corporation Sailing South. CCLThis one is posed for more drops now or soon. It's a zigzag again and indicators support the view for further drops. More goals could be drawn in, but its more prudent to limit yourself with three or four on a regular basis. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:CCLShort
by Rykin_Capital
HALBERD CORPORATION· Current Price – $0.0419 · Best Case Scenario PT over 1$ · Market Cap – $11 million · Debt – 0 Halbert Corporation Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the technology to cure diseases like, Covid-19, PTSD, Cancer, CTE, tuberculosis, malaria, strokes and heart attacks, blood sepsis, Alzheimer’s Disease. In the last 8 months they have secured 7 provisional patents (which give the global rights) to technology of treating severe Covid-19 patients, Covid-19 nasal spray, antibody cocktail to boost immune system against Covid - 19 and recently developed two new antibodies that no other big pharma has, which allows them detect Covid-19 in matter of minutes using saliva or blood samples. Furthermore, are working with $GRPS to develop anti-addiction patches (alcohol, drugs, nicotine). To achieve their further goals they have carefully selected to partner with Arizona State University (who have won the first place in innovation for the last 6 years going in the USA, higher than MIT or Stanford). This partnership has already delivered amazing milestones and they are already working towards filing for new joint provisional patents. Halbert has 0 debt, yes ZERO and been receiving funding in 2 million chunk donations due to promising results. Halberd’s corporate charter also prohibits them from issuing any kind of convertible financial instrument, debt or preferred stock, however the corporation shall be able to issue warrants or options. Management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Furthermore, the ultimate catalyst, which seems quite likely is for Halbert to partner or licence their technology to one of the big pharma as the CEO, William has mentioned so on multiple occasions. In the past, he has been approached by the big pharma (Pfizer and Novartis), and hopes the same will happen with their revolutionary technology. Issued Patents 2014 - Sequential Extracorporeal Treatment of Bodily Fluids 2015 - Utilization of Stents for the Treatment of Blood Borne Carcinomas Provisional Patents 11/2020 - Fluorescent Antibody’s in Covid-19 Detection & Treatment 10/2020 - Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus). 10/2020 - Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus 09/2020 - Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans 04/2020 - Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus 04/2020 - Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients 03/2020 - Method for Treating and Curing Covid-19 Infection Future Patents During podcasts and interviews the CEO said he will announce another 2 patents soon. They are waiting to achieve provisional status to ensure the technology is safe. Further patents are in the pipeline as CEO’s devised a strategy to secure as many patents as they can, of which they could then either licence or partner on developing on joint ventures with big pharma. Upcoming Catalyst 2021 · 2 patent provisional applications yet to be announced · Development of antibody cocktail vitamins to boost immune system against Covid-19 (Q2 launch and start to generate revenue) · Development of Covid-19 Nasal Spray · Commercial development of Covid-19 test using saliva or blood (takes only a minute no nasal swap which is uncomfortable) · Patent Licencing to other pharma companies – they produced antibodies that are stronger than some of the big pharma · Partnerships and joint ventures with other organizations · Discovery of new treatments and patent fillings · Further development of extracorporeal technology to treat cancer, PTSD, Alzheimer’s, blood sepsis, CTE · Anti-addiction patches Sociability Factor In penny stock market, especially during current times (rise of social media and social traders) the CEO’s or the organization being sociable, sharing achievements, milestones, ethos and so on can have a massive impact on the share value. In this regard, Halberd’s corporation in my view would score high points. They tend to release anywhere between 2/5 press releases a month in which various milestones would be announced via text, video interviews or podcasts. Senior Leadership Team The CEO’s aim was to ensure that they develop a very cohesive team of talented people to achieve greatness. Here below I have listed a few KEY members including bio snapshots. Business Advisory Board The CEO – based on the videos and podcasts that are available (6+) of William A. Hartman sounds very ambitious and driven on a mission to be the best in the industry and revolutionize medicine. He believes Halberd corporation share value should be worth $1 per share. This may sound like very ambitious venture for some, however, let us not forget he founded and headed separate business group within TRW Automotive with plants in the U.S., Mexico and Europe that produced combined annual sales of $1.3 Billion – this shows extreme capability. He has also worked as COO for Nanologix, Inc, President and CEO of Premier Biomedical. I would recommend checking out any of his interviews to feel his passion. Carl Eller - retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association, was drafted in 1964 as the league’s 6th pick overall by the Minnesota Vikings, he became a major factor as a defensive end with the unit known as the “Purple People Eaters.” Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement. Alec Torelli - is an entrepreneur, author, motivational speaker and professional poker player who has worked with various companies to apply his life experiences/lessons from poker, in a practical manner, to carry out their corporate visions, increase sales and/or improve service delivery while creating meaningful lives for their employees. Scientific Advisory Board Mitchell S. Felder, MD - is a prolific inventor. He is a Board Certified Neurologist and former CEO, President, Chairman and founder of Infectech and Nanologix, and currently serves as Locum Tenens Attending Neurologist with UPMC Pennsylvania Dr. Felder has authored or co-authored six publications, three studies and has currently 21 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011. Dr. Qiang (Shawn) Chen, who is the Principal Investigator at ASU, in charge of the research and development for Halberd Corp: Take a look at his research projects over the last 4-5 years and you see why this HALB/ASU cooperation is a marriage made in heaven. Only weeks ago, Halberd signed another R&D-agreement with GreenBioAZ inc, it's a start up from Arizona State University and will do research for Halberd's radiofrequency technology. Dr. Chen is CEO of GreenBioAZ Patricio Reyes, MD, FAAN - a board certified neurologist and neuropathologist, and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona and is a Board Member of the Retired National Football League Players Association. Dr. Reyes is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. HALB has access to the VA Hospital Group because of Dr. Reyes. Timeline of Key Press Releases I have gone through the list of all of their press releases (they post regularly) and compiled key updates here below: April 6, 2020 - Halberd announces agreement to retire 192,000,000 outstanding common shares and reduced authorized shares of common stock to 1,000,000,000. April 8, 2020 – Halberd, Premier Biomedical ($BIEI) and Gold River Productions ($GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch. July 1, 2020 - Halberd establishes United Kingdom subsidiary to facilitate access to European research facilities and markets to establish a global footprint. July 13, 2020 - Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt, or preferred stock. August 4, 2020 - Halberd secures $2 Million for Covid-19 Research August 31, 2020 - Halberd signed an agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. September 21, 2020 - Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen September 24, 2020 - Successful creation of a fluorescent antibody, that will help them create a rapid Covid-19 test using saliva or a drop of blood. This approach will allow for accurate test results in a matter of minutes – believe travel industry may benefit from this approach. October 8th, 2020 – CEO’s letter of updates and accomplishments October 13, 2020 – Halberd and ASU Develop Antibody Against Covid-19, pursuing new joint patent. October 19, 2020 – in process to filing a new joint patent with AUS for creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. This protein will allow extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood. October 29, 2020 – Strategic plan curing blood sepsis, Alzheimer’s Disease, Heart Attack and Stroke using extracorporeal process November 12, 2020 – Patent pending for Covid-19 detection test from saliva or blood in minutes. December 1, 2020 – Halberd re-organizes advisory board. December 17, 2020 - Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19 December 23, 2020 - Halberd Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein – “Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem” January 4, 2021 - Halberd Corporation 2020 Year End CEO Letter, looking forward to 2021 January 14, 2021 - Halberd Develops Medication to Boost Immune System Against Covid-19 February 16, 2021 - Halberd has engaged GreenBioAZ to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease. March 2, 2021 - Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater - “We are excited about the progress being made in developing Halberd’s effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best-known competitive SARS-COV-2 antibodies. Since posting links may take an excessive amount of space here, you can find all the press releases here and search by date, plenty more to see that are not included in my post - Hope people found this helpful and I look forward to seeing what the future holds for $HALB!
OTC:HALBLong
by headdeveloper33
1
Kraft Heinz co. Investment opportunity or bad business Is Kraft Heinz co a investment of a lifetime or a death sentence? Warren Buffett bought 26.70 percent of the company at 72 dollars a share. He openly stated he was wrong about Kraft in a couple different ways. Kraft Heinz co is 30.1 billion in dept and only worth 39.1 billion they make around 6 billion a year and currently coming out with a new line of kraft baby food. How much revenue is that going to bring? I don't think kraft will go out of business however I do think it will be several years to make a turn around. That is my prediction what's your thoughts please share you knowledge on the subject.
NASDAQ:KHCLong
by MatthewV
nVidia | 60%Countercyclical Trade? Corporate Rally Before CrisisEarlier this year we prepared and then shorted nVidia after discovering the technical bubble: This bubble is now in the process of bursting. However, nothing goes to heck in a straight line, and we may have an opportunity to get long for a rebound trade before the stock continues its downturn. Watch the gaps that have formed on the 4HR, which could very well indicate where we may trade as we go back to test the support or resistance at those levels. Above 143 we are bullish, below 132 we are likely consolidating or may breakdown further. This idea follows our thinking related to the overall market measured through the Nasdaq (NDX):
NASDAQ:NVDALong
by Trader6127
7
A Brief Summary of the Overall Outlook of CGC StockCGC will reverse its downward trend when the price gets to about $27 per share; this is when it will reverse back toward its mean of around $28 per share. The stock will remain here for a while until there is a positive news catalyst that will catapult the stock back up toward the $40 area where it will stay for a day before it begins its downward trend back toward its weekly moving average of $28 per share. At the present time, investors who bought into the Canadian legalization rumor/hype are now taking profits and will eventually buy back the stock when it gets to the $27 price level. These inferences were devised by employing the Mstardom Finance proprietary trading strategy.
C
by mstardom